HC
LGND icon

Henshaw Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Henshaw Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,668
Closed -$827K – 219
2025
Q3 		$827K Sell
4,668
-1,728
-27% -$257K 0.03% 125
2025
Q2 		$727K Hold
6,396
– – 0.03% 185
2025
Q1 		$672K Hold
6,396
– – 0.03% 188
2024
Q4 		$685K Hold
6,396
– – 0.03% 167
2024
Q3 		$640K Hold
6,396
– – 0.03% 184
2024
Q2 		$539K Buy
6,396
+102
+2% +$8.12K 0.02% 166
2024
Q1 		$460K Hold
6,294
– – 0.02% 185
2023
Q4 		$450K Hold
6,294
– – 0.02% 191
2023
Q3 		$377K Buy
6,294
+2,747
+77% +$181K 0.02% 188
2023
Q2 		$256K Buy
3,547
+321
+10% +$24.1K 0.01% 205
2023
Q1 		$237K Hold
3,226
– – 0.01% 211
2022
Q4 		$215K Sell
3,226
-1,945
-38% -$126K 0.01% 223
2022
Q3 		$278K Hold
5,171
– – 0.02% 214
2022
Q2 		$288K Hold
5,171
– – 0.02% 229
2022
Q1 		$363K Buy
5,171
+838
+19% +$60.8K 0.02% 211
2021
Q4 		$418K Hold
4,333
– – 0.02% 196
2021
Q3 		$377K Hold
4,333
– – 0.02% 206
2021
Q2 		$355K Hold
4,333
– – 0.02% 242
2021
Q1 		$412K Sell
4,333
-835
-16% -$78.9K 0.03% 199
2020
Q4 		$321K Hold
5,168
– – 0.02% 242
2020
Q3 		$307K Hold
5,168
– – 0.02% 216
2020
Q2 		$361K Buy
5,168
+524
+11% +$33.2K 0.03% 185
2020
Q1 		$211K Buy
+4,644
New +$263K 0.02% 250
2019
Q2 		– Sell
-2,754
Closed -$216K – 299
2019
Q1 		$216K Buy
+2,754
New +$209K 0.02% 258

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Henshaw Capital's LGND Position: Q4 2025 in Review

Henshaw Capital sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 4,668 shares — an estimated $827K sold.

Henshaw Capital first reported a position in LGND in Q1 2019 and held it in 24 quarters. The position peaked at $827K in Q3 2025. 350 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

  • Henshaw Capital reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Henshaw Capital sold 4,668 Ligand Pharmaceuticals shares in Q4 2025, an estimated $827K.
  • Henshaw Capital first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 24 quarters.
  • Henshaw Capital's Ligand Pharmaceuticals position peaked at $827K in Q3 2025.
  • 350 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on Henshaw Capital's 13F filing for Q4 2025, filed 28 May 2026.